Newer
Older
Digital_Repository / Misc / Mass downloads / UTas / 2442.html
  1. <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  2. "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
  3. <html>
  4. <head>
  5. <title>UTas ePrints - A role for the tissue factor pathway in the pathogenesis of the antiphospholipid syndrome</title>
  6. <script type="text/javascript" src="http://eprints.utas.edu.au/javascript/auto.js"><!-- padder --></script>
  7. <style type="text/css" media="screen">@import url(http://eprints.utas.edu.au/style/auto.css);</style>
  8. <style type="text/css" media="print">@import url(http://eprints.utas.edu.au/style/print.css);</style>
  9. <link rel="icon" href="/images/eprints/favicon.ico" type="image/x-icon" />
  10. <link rel="shortcut icon" href="/images/eprints/favicon.ico" type="image/x-icon" />
  11. <link rel="Top" href="http://eprints.utas.edu.au/" />
  12. <link rel="Search" href="http://eprints.utas.edu.au/cgi/search" />
  13. <meta content="Lean, Sim Yee" name="eprints.creators_name" />
  14. <meta content="Adams, M.J." name="eprints.creators_name" />
  15. <meta content="" name="eprints.creators_id" />
  16. <meta content="Murray.Adams@utas.edu.au" name="eprints.creators_id" />
  17. <meta content="article" name="eprints.type" />
  18. <meta content="2007-11-15 01:28:18" name="eprints.datestamp" />
  19. <meta content="2008-01-08 15:30:00" name="eprints.lastmod" />
  20. <meta content="show" name="eprints.metadata_visibility" />
  21. <meta content="A role for the tissue factor pathway in the pathogenesis
  22. of the antiphospholipid syndrome" name="eprints.title" />
  23. <meta content="pub" name="eprints.ispublished" />
  24. <meta content="321008" name="eprints.subjects" />
  25. <meta content="restricted" name="eprints.full_text_status" />
  26. <meta content="Antiphospholipid antibodies; Antiphospholipid syndrome; Thrombosis; Tissue factor; Tissue factor pathway inhibitor" name="eprints.keywords" />
  27. <meta content="The antiphospholipid syndrome (aPS) is a systemic autoimmune disorder that is characterised by
  28. laboratory markers of antiphospholipid antibodies (aPL) as well as clinical manifestations such as arterial
  29. and venous thrombosis, recurrent pregnancy loss and thrombocytopaenia. Although it is unclear precisely
  30. what mechanism(s) lead to thrombosis in aPS, it is probable that the contribution of aPL such as anti-β-2-
  31. glycoprotein-1 (anti-β2GP1) is signifi cant. Indeed, there is increasing evidence that aPL may interfere with
  32. the tissue factor (TF) pathway of blood coagulation and its natural regulator tissue factor pathway inhibitor
  33. (TFPI), thus contributing toward the development of thrombosis in aPS. This paper will therefore review
  34. 1) the TF pathway of blood coagulation and TFPI, 2) clinical and laboratory aspects of aPL and aPS,
  35. and 3) interactions of aPL with the TF pathway, to highlight the potential signifi cance of these in the
  36. pathogenesis of aPS." name="eprints.abstract" />
  37. <meta content="2007-08" name="eprints.date" />
  38. <meta content="published" name="eprints.date_type" />
  39. <meta content="Australian Journal of Medical Science" name="eprints.publication" />
  40. <meta content="28" name="eprints.volume" />
  41. <meta content="3" name="eprints.number" />
  42. <meta content="99-107" name="eprints.pagerange" />
  43. <meta content="TRUE" name="eprints.refereed" />
  44. <meta content="1038-1643" name="eprints.issn" />
  45. <meta content="http://www.aims.org.au/c/" name="eprints.official_url" />
  46. <meta content="1. Adams, M., Breckler, L., Stevens, P., Thom, J., Baker, R., Oostryck, R.
  47. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation
  48. (2004) Haematologica, 89 (8), pp. 985-990. Cited 7 times.
  49.  
  50. 2. Adams, M.J., Donohoe, S., Mackie, I.J., Machin, S.J.
  51. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome
  52. (2001) British Journal of Haematology, 114 (2), pp. 375-379. Cited 12 times.
  53. doi: 10.1046/j.1365-2141.2001.02923.x
  54.  
  55. 3. Amengual, O., Atsumi, T., Khamashta, M.A., Hughes, G.R.V.
  56. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
  57. (1998) Thrombosis and Haemostasis, 79 (2), pp. 276-281. Cited 141 times.
  58.  
  59. 4. Asherson, R.A.
  60. A &quot;primary&quot; antiphospholipid syndrome?
  61. (1988) The Journal of rheumatology, 15 (12), pp. 1742-1746. Cited 129 times.
  62.  
  63. 5. Asherson, R.A., Khanashta, M.A., Hughes, G.R.V.
  64. Antiphospholipid antibodies, lupus-like disease and the 'primary' antiphospholipid syndrome
  65. (1989) Clinical Rheumatology, 8 (1), pp. 115-117. Cited 4 times.
  66.  
  67. 6. Bajaj, M.S., Birktoft, J.J., Steer, S.A., Bajaj, S.P.
  68. Structure and biology of tissue factor pathway inhibitor
  69. (2001) Thrombosis and Haemostasis, 86 (4), pp. 959-972. Cited 99 times.
  70.  
  71. 7. Bertolaccini, M.L., Roch, B., Amengual, O., Atsumi, T., Khamashta, M.A., Hughes, G.R.V.
  72. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome
  73. (1998) British Journal of Rheumatology, 37 (11), pp. 1229-1232. Cited 29 times.
  74.  
  75. 8. Bidot, C.J., Jy, W., Horstman, L.L., Huisheng, H., Jimenez, J.J., Yaniz, M., Ahn, Y.S.
  76. Factor VII/VIIa: A new antigen in the anti-phospholipid antibody syndrome
  77. (2003) British Journal of Haematology, 120 (4), pp. 618-626. Cited 13 times.
  78.  
  79. 9. Bowie, W.E.J., Thompson, J.H., Pascuzi, C.A., Owen, C.A.
  80. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants
  81. (1963) J Lab Clini Med, 62, pp. 416-430. Cited 173 times.
  82.  
  83.  
  84. 10. Branch, D.W.
  85. Antiphospholipid antibodies and fetal compromise
  86. (2004) Thrombosis Research, 114 (5-6 SPEC. ISS.), pp. 415-418. Cited 8 times.
  87. doi: 10.1016/j.thromres.2004.08.005
  88.  
  89. 11. Broze Jr., G.J.
  90. Tissue factor pathway inhibitor gene disruption
  91. (1998) Blood Coagulation and Fibrinolysis, 9 (SUPPL. 1), pp. S89-S92. Cited 18 times.
  92.  
  93. 12. Broze Jr., G.J., Warren, L.A., Girard, J.J., Miletich, J.P.
  94. Isolation of the lipoprotein associated coagulation inhibitor produced by HepG2 (human hepatoma) cells using bovine factor Xa affinity chromatography.
  95. (1987) Thrombosis Research, 48 (2), pp. 253-259. Cited 4 times.
  96.  
  97. 13. Broze Jr., G.J.
  98. Tissue factor pathway inhibitor
  99. (1995) Thrombosis and Haemostasis, 74 (1), pp. 90-93. Cited 206 times.
  100.  
  101. 14. Broze Jr., G.J.
  102. Tissue factor pathway inhibitor and the current concept of blood coagulation
  103. (1995) Blood Coagulation and Fibrinolysis, 6 (SUPPL. 1), pp. S7-S13. Cited 116 times.
  104.  
  105. 15. Broze Jr., G.J., Miletich, J.P.
  106. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells
  107. (1987) Proceedings of the National Academy of Sciences of the United States of America, 84 (7), pp. 1886-1890. Cited 28 times.
  108.  
  109. 16. Broze Jr., G.J., Lange, G.W., Duffin, K.L., MacPhail, L.
  110. Heterogeneity of plasma tissue factor pathway inhibitor
  111. (1994) Blood Coagulation and Fibrinolysis, 5 (4), pp. 551-559. Cited 57 times.
  112.  
  113. 17. Camerota, A.J., Creasey, A.A., Patla, V., Larkin, V.A., Fink, M.P.
  114. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
  115. (1998) Journal of Infectious Diseases, 177 (3), pp. 668-676. Cited 63 times.
  116.  
  117. 18. Carreras, L.O., Forastiero, R.R., Martinuzzo, M.E.
  118. Which are the best biological markers of the antiphospholipid syndrome?
  119. (2000) Journal of Autoimmunity, 15 (2), pp. 163-172. Cited 61 times.
  120. doi: 10.1006/jaut.2000.0401
  121.  
  122. 19. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RHWM, de Groot Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris J-C, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa M-C, Hughes GRV, Ingelmo M. 2002. Antiphospholipid syndrome: clinical and immunological manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum; 46:1019-1027.
  123.  
  124.  
  125. 20. Cho, C.-S., Cho, M.-L., Chen, P.P., Min, S.-Y., Hwang, S.-Y., Park, K.-S., Kim, W.-U., (...), Kim, H.-Y.
  126. Antiphospholipid antibodies induce monocyte chemoattractant protein-1 in endothelial cells
  127. (2002) Journal of Immunology, 168 (8), pp. 4209-4215. Cited 26 times.
  128.  
  129. 21. Conley, C.L., Hartman, R.C.
  130. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematous
  131. (1952) J Clin Invest, 31, pp. 621-622. Cited 170 times.
  132.  
  133.  
  134. 22. Creasey, A.A., Chang, A.C.K., Feigen, L., Wun, T.-C., Taylor Jr., F.B., Hinshaw, L.B.
  135. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
  136. (1993) Journal of Clinical Investigation, 91 (6), pp. 2850-2860. Cited 336 times.
  137.  
  138. 23. Cuadrado, M.J., López-Pedrera, C., Khamashta, M.A., Camps, M.T., Tinahones, F., Torres, A., Hughes, G.R.V., (...), Velasco, F.
  139. Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression
  140. (1997) Arthritis and Rheumatism, 40 (5), pp. 834-841. Cited 99 times.
  141.  
  142. 24. Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ, Jr., Warren T, G., Wun T-C. 1990. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood; 76:1538-1545.
  143.  
  144.  
  145. 25. De Jonge, E., Dekkers, P.E.P., Creasey, A.A., Hack, C.E., Paulson, S.K., Karim, A., Kesecioglu, J., (...), Van Der Poll, T.
  146. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
  147. (2000) Blood, 95 (4), pp. 1124-1129. Cited 153 times.
  148.  
  149. 26. Dobado-Berrios, P.M., Löpez-Pedrera, C., Velasco, F., Aguirre, M.A., Torres, A., Cuadrado, M.J.
  150. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome
  151. (1999) Thrombosis and Haemostasis, 82 (6), pp. 1578-1582. Cited 49 times.
  152.  
  153. 27. Durrani, O.M., Gordon, C., Murray, P.I.
  154. Primary anti-phospholipid antibody syndrome (APS): Current concepts
  155. (2002) Survey of Ophthalmology, 47 (3), pp. 215-238. Cited 18 times.
  156. doi: 10.1016/S0039-6257(02)00289-8
  157.  
  158. 28. Forastiero, R.R., Martinuzzo, M.E., Broze, G.J.
  159. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome.
  160. (2003) Journal of thrombosis and haemostasis : JTH, 1 (4), pp. 718-724. Cited 16 times.
  161.  
  162. 29. Galli, M.
  163. Antiphospholipid antibodies and thrombosis: Do test patterns identify the patients' risk?
  164. (2004) Thrombosis Research, 114 (5-6 SPEC. ISS.), pp. 597-601. Cited 11 times.
  165. doi: 10.1016/j.thromres.2004.08.009
  166.  
  167. 30. Girard, T.J., Warren, L.A., Novotny, W.F., Likert, K.M., Brown, S.G., Miletich, J.P., Broze Jr., G.J.
  168. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
  169. (1989) Nature, 338 (6215), pp. 518-520. Cited 215 times.
  170.  
  171. 31. Godeau, B., Piette, J.-C., Fromont, P., Intrator, L., Schaeffer, A., Bierling, P.
  172. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome
  173. (1997) British Journal of Haematology, 98 (4), pp. 873-879. Cited 39 times.
  174.  
  175. 32. Hamik, A., Setiadi, H., Bu, G., McEver, R.P., Morrissey, J.H.
  176. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein
  177. (1999) Journal of Biological Chemistry, 274 (8), pp. 4962-4969. Cited 52 times.
  178. doi: 10.1074/jbc.274.8.4962
  179.  
  180. 33. Harris, E.N., Gharavi, A.E., Boey, M.L.
  181. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
  182. (1983) Lancet, 2 (8361), pp. 1211-1214. Cited 502 times.
  183.  
  184. 34. Haskel, E.J., Torr, S.R., Day, K.C., Palmier, M.O., Wun, T.-C., Sobel, B.E., Abendschein, D.R.
  185. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor
  186. (1991) Circulation, 84 (2), pp. 821-827. Cited 76 times.
  187.  
  188. 35. Hasselaar, P., Derksen, R.H.W.M., Oosting, J.D., Blokzijl, L., De Groot, P.G.
  189. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells
  190. (1989) Thrombosis and Haemostasis, 62 (2), pp. 654-660. Cited 36 times.
  191.  
  192. 36. Hjort, P.F.
  193. Intermediate reactions in the coagulation of the blood with tissue thromboplastin
  194. (1954) Scand J Clin Lab Invest, 9, pp. 1-128. Cited 35 times.
  195.  
  196.  
  197. 37. Hughes, G.R., Harris, N.N., Gharavi, A.E.
  198. The anticardiolipin syndrome.
  199. (1986) The Journal of rheumatology, 13 (3), pp. 486-489. Cited 376 times.
  200.  
  201. 38. Jacobsen, E.M., Sandset, P.M., Wisløff, F.
  202. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor
  203. (1999) Thrombosis Research, 94 (4), pp. 213-220. Cited 12 times.
  204. doi: 10.1016/S0049-3848(98)00195-9
  205.  
  206. 39. Kobayashi, M., Wada, H., Wakita, Y., Shimura, M., Nakase, T., Hiyoyama, K., Nagaya, S., (...), Shiku, H.
  207. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura
  208. (1995) Thrombosis and Haemostasis, 73 (1), pp. 10-14. Cited 37 times.
  209.  
  210. 40. Koyama, T., Nishida, K., Ohdama, S., Sawada, M., Murakami, N., Hirosawa, S., Kuriyama, R., (...), Aoki, N.
  211. Determination of plasma tissue factor antigen and its clinical significance
  212. (1994) British Journal of Haematology, 87 (2), pp. 343-347. Cited 116 times.
  213.  
  214. 41. Lean, S.Y., Ellery, P., Ivey, L., Thom, J., Oostryck, R., Leahy, M., Baker, R., (...), Adams, M.
  215. The effects of tissue factor pathway inhibitor and anti-β-2- glycoprotein-I IgG on thrombin generation
  216. (2006) Haematologica, 91 (10), pp. 1360-1366.
  217.  
  218. 42. Loeb, L., Fleisher, M.S., Tuttle, L.
  219. The interaction between blood serum and tissue extract in the coagulation of blood. I. The combined action of serum and tissue extract on fluoride, hirudin, and peptone plasma; the effect of heating on serum
  220. (1922) J Bioll Chem, 51, pp. 461-483. Cited 2 times.
  221.  
  222.  
  223. 43. Lupu, C., Hu, X., Lupu, F.
  224. Caveolin-1 enhances tissue factor pathway inhibitor exposure and function on the cell surface
  225. (2005) Journal of Biological Chemistry, 280 (23), pp. 22308-22317. Cited 5 times.
  226. doi: 10.1074/jbc.M503333200
  227.  
  228. 44. Mackworth-Young, C.G.
  229. Antiphospholipid syndrome: Multiple mechanisms
  230. (2004) Clinical and Experimental Immunology, 136 (3), pp. 393-401. Cited 30 times.
  231.  
  232. 45. Malaviya, A.N.
  233. Antiphospholipid (Hughes) syndrome: A review with update
  234. (2003) APLAR J Rheumatol, 6, pp. 160-169. Cited 2 times.
  235.  
  236. 46. Manson, J.J., Isenberg, D.A.
  237. Antiphospholipid syndrome
  238. (2003) International Journal of Biochemistry and Cell Biology, 35 (7), pp. 1015-1020. Cited 7 times.
  239. doi: 10.1016/S1357-2725(02)00313-8
  240.  
  241. 47. McIntyre, J.A., Wagenknecht, D.R., Faulk, W.P.
  242. Antiphospholipid antibodies: Discovery, definitions, detection and disease
  243. (2003) Progress in Lipid Research, 42 (3), pp. 176-237. Cited 24 times.
  244. doi: 10.1016/S0163-7827(02)00048-6
  245.  
  246. 48. McVey, J.H.
  247. Tissue Factor pathway
  248. (1999) Bailliere's Best Practice and Research in Clinical Haematology, 12 (3), pp. 361-372. Cited 40 times.
  249. doi: 10.1053/beha.1999.0030
  250.  
  251. 49. Meroni, P.L., Riboldi, P.
  252. Pathogenic mechanisms of antiphospholipid syndrome: A new autoimmune disease
  253. (2004) Drug Discovery Today: Disease Mechanisms, 1 (3), pp. 309-314. Cited 3 times.
  254. doi: 10.1016/j.ddmec.2004.11.006
  255.  
  256. 50. Mine, S., Yamazaki, T., Miyata, T., Hara, S., Kato, H.
  257. Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor
  258. (2002) Biochemistry, 41 (1), pp. 78-85. Cited 14 times.
  259. doi: 10.1021/bi011299g
  260.  
  261. 51. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derkesen, R.H.W.M., (...), Krilis, S.A.
  262. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
  263. (2006) Journal of Thrombosis and Haemostasis, 4 (2), pp. 295-306. Cited 204 times.
  264. doi: 10.1111/j.1538-7836.2006.01753.x
  265.  
  266. 52. Morrissey, J.H.
  267. Tissue factor: An enzyme cofactor and a true receptor
  268. (2001) Thrombosis and Haemostasis, 86 (1), pp. 66-74. Cited 110 times.
  269.  
  270. 53. Mueller, J.F., Ratnoff, O., Heinle, R.W.
  271. Observations on the characteristics of an unusual circulating anticoagulant
  272. (1951) J Lab Clin Med, 38, pp. 254-261. Cited 6 times.
  273.  
  274. 54. Nimmo, M.C., Carter, C.J.
  275. The antiphospolipid syndrome. A riddle wrapped in a mystery inside an enigma
  276. (2003) Clinical and Applied Immunology Reviews, 4 (2), pp. 125-140. Cited 5 times.
  277. doi: 10.1016/S1529-1049(03)00047-3
  278.  
  279. 55. Oosting, J.D., Derksen, R.H.W.M., Blokzijl, L., Sixma, J.J., De Groot, P.G.
  280. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity - Studies in a thrombosis model
  281. (1992) Thrombosis and Haemostasis, 68 (3), pp. 278-284. Cited 50 times.
  282.  
  283. 56. Pangborn, M.C.
  284. A new serologically active phospholipid from beef heart
  285. (1941) Procf Soc Exp Biol Med, 48, pp. 484-486. Cited 59 times.
  286.  
  287.  
  288. 57. Petri, M.
  289. Epidemiology of the antiphospholipid antibody syndrome
  290. (2000) Journal of Autoimmunity, 15 (2), pp. 145-151. Cited 122 times.
  291. doi: 10.1006/jaut.2000.0409
  292.  
  293. 58. Rand, J.H.
  294. The Antiphospholipid Syndrome
  295. (2003) Annual Review of Medicine, 54, pp. 409-424. Cited 36 times.
  296.  
  297. 59. Rao, L.V.M., Rapaport, S.I.
  298. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation
  299. (1987) Blood, 69 (2), pp. 645-651. Cited 67 times.
  300.  
  301. 60. Rosendaal, F.R.
  302. Thrombosis in the young: Epidemiology and risk factors. A focus on venous thrombosis
  303. (1997) Thrombosis and Haemostasis, 78 (1), pp. 1-6. Cited 170 times.
  304.  
  305. 61. Roubey, R.A.S.
  306. Tissue factor pathway and the antiphospholipid syndrome
  307. (2000) Journal of Autoimmunity, 15 (2), pp. 217-220. Cited 28 times.
  308. doi: 10.1006/jaut.2000.0397
  309.  
  310. 62. Rustin, M.H.A., Bull, H.A., Machin, S.J., Isenberg, D.A., Snaith, M.L., Dowd, P.M.
  311. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity
  312. (1988) Journal of Investigative Dermatology, 90 (5), pp. 744-748. Cited 18 times.
  313.  
  314. 63. Safa, O., Morrissey, J.H., Esmon, C.T., Esmon, N.L.
  315. Factor VIIa/tissue factor generates a form of factor V with unchanged specific activity, resistance to activation by thrombin, and increased sensitivity to activated protein C
  316. (1999) Biochemistry, 38 (6), pp. 1829-1837. Cited 7 times.
  317. doi: 10.1021/bi981730a
  318.  
  319. 64. Salemink, I., Blezer, R., Willems, G.M., Galli, M., Bevers, E., Lindhout, T.
  320. Antibodies to β-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor
  321. (2000) Thrombosis and Haemostasis, 84 (4), pp. 653-656. Cited 26 times.
  322.  
  323. 65. Schwartz, A.L., Broze Jr., G.J.
  324. Tissue factor pathway inhibitor endocytosis
  325. (1997) Trends in Cardiovascular Medicine, 7 (7), pp. 234-239. Cited 6 times.
  326. doi: 10.1016/S1050-1738(97)00083-2
  327.  
  328. 66. Sevinsky, J.R., Mohan Rao, L.V., Ruf, W.
  329. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway
  330. (1996) Journal of Cell Biology, 133 (2), pp. 293-304. Cited 145 times.
  331. doi: 10.1083/jcb.133.2.293
  332.  
  333. 67. Shimura, M., Wada, H., Wakita, Y., Nakase, T., Hiyoyama, K., Nagaya, S., Mori, Y., (...), Shiku, H.
  334. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
  335. (1997) American Journal of Hematology, 55 (4), pp. 169-174. Cited 23 times.
  336. doi: 10.1002/(SICI)1096-8652(199707)55:4<169::AID-AJH1>3.0.CO;2-Q
  337.  
  338. 68. Di Simone, N., Raschi, E., Testoni, C., Castellani, R., D'Asta, M., Shi, T., Krilis, S.A., (...), Meroni, P.L.
  339. Pathogenic role of anti-β2-glycoprotein I antibodies in antiphospholipid associated fetal loss: Characterisation of β2-glycoprotein I binding to trophoblast cells and functional effects of anti-β2- glycoprotein I antibodies in vitro
  340. (2005) Annals of the Rheumatic Diseases, 64 (3), pp. 462-467. Cited 14 times.
  341. doi: 10.1136/ard.2004.021444
  342.  
  343. 69. Takahashi, H., Sato, N., Shibata, A.
  344. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: Comparison of its behavior with plasma tissue factor
  345. (1995) Thrombosis Research, 80 (4), pp. 339-348. Cited 20 times.
  346. doi: 10.1016/0049-3848(95)00185-T
  347.  
  348. 70. Tannenbaum, S.H., Finko, R., Cines, D.B.
  349. Antibody and immune complexes induce tissue factor production by human endothelial cells
  350. (1986) Journal of Immunology, 137 (5), pp. 1532-1537. Cited 80 times.
  351.  
  352. 71. Triplett, D.A.
  353. Antiphospholipid antibodies
  354. (2002) Archives of Pathology and Laboratory Medicine, 126 (11), pp. 1424-1429. Cited 34 times.
  355.  
  356. 72. Van't Veer, C., Mann, K.G.
  357. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II
  358. (1997) Journal of Biological Chemistry, 272 (7), pp. 4367-4377. Cited 81 times.
  359. doi: 10.1074/jbc.272.7.4367
  360.  
  361. 73. Warren, D.L., Morrissey, J.H., Neuenschwander, P.F.
  362. Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: Generation of an inactive factor VIII cofactor
  363. (1999) Biochemistry, 38 (20), pp. 6529-6536. Cited 2 times.
  364. doi: 10.1021/bi983033o
  365.  
  366. 74. Wassermann, A., Niesser, A., Bruck, C.
  367. Eine serodiagnostiche Reaktionbei syphilis
  368. (1906) Deutsche Med Wochenschr, 32, pp. 745-746. Cited 73 times.
  369.  
  370.  
  371. 75. Wilson, W.A., Gharavi, A.E., Koike, T., Lockshin, M.D., Branch, D.W., Piette J.-, C., Brey, R., (...), Khamashta, M.A.
  372. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International Workshop
  373. (1999) Arthritis and Rheumatism, 42 (7), pp. 1309-1311. Cited 1284 times.
  374. doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
  375.  
  376. 76. Wun, T.-C., Kretzmer, K.K., Girard, T.J., Miletich, J.P., Broze Jr., G.J.
  377. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
  378. (1988) Journal of Biological Chemistry, 263 (13), pp. 6001-6004. Cited 146 times." name="eprints.referencetext" />
  379. <meta content="Lean, Sim Yee and Adams, M.J. (2007) A role for the tissue factor pathway in the pathogenesis of the antiphospholipid syndrome. Australian Journal of Medical Science, 28 (3). pp. 99-107. ISSN 1038-1643" name="eprints.citation" />
  380. <meta content="http://eprints.utas.edu.au/2442/1/Adams_and_Lean_2007.pdf" name="eprints.document_url" />
  381. <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
  382. <meta content="A role for the tissue factor pathway in the pathogenesis
  383. of the antiphospholipid syndrome" name="DC.title" />
  384. <meta content="Lean, Sim Yee" name="DC.creator" />
  385. <meta content="Adams, M.J." name="DC.creator" />
  386. <meta content="321008 Haematology" name="DC.subject" />
  387. <meta content="The antiphospholipid syndrome (aPS) is a systemic autoimmune disorder that is characterised by
  388. laboratory markers of antiphospholipid antibodies (aPL) as well as clinical manifestations such as arterial
  389. and venous thrombosis, recurrent pregnancy loss and thrombocytopaenia. Although it is unclear precisely
  390. what mechanism(s) lead to thrombosis in aPS, it is probable that the contribution of aPL such as anti-β-2-
  391. glycoprotein-1 (anti-β2GP1) is signifi cant. Indeed, there is increasing evidence that aPL may interfere with
  392. the tissue factor (TF) pathway of blood coagulation and its natural regulator tissue factor pathway inhibitor
  393. (TFPI), thus contributing toward the development of thrombosis in aPS. This paper will therefore review
  394. 1) the TF pathway of blood coagulation and TFPI, 2) clinical and laboratory aspects of aPL and aPS,
  395. and 3) interactions of aPL with the TF pathway, to highlight the potential signifi cance of these in the
  396. pathogenesis of aPS." name="DC.description" />
  397. <meta content="2007-08" name="DC.date" />
  398. <meta content="Article" name="DC.type" />
  399. <meta content="PeerReviewed" name="DC.type" />
  400. <meta content="application/pdf" name="DC.format" />
  401. <meta content="http://eprints.utas.edu.au/2442/1/Adams_and_Lean_2007.pdf" name="DC.identifier" />
  402. <meta content="http://www.aims.org.au/c/" name="DC.relation" />
  403. <meta content="Lean, Sim Yee and Adams, M.J. (2007) A role for the tissue factor pathway in the pathogenesis of the antiphospholipid syndrome. Australian Journal of Medical Science, 28 (3). pp. 99-107. ISSN 1038-1643" name="DC.identifier" />
  404. <meta content="http://eprints.utas.edu.au/2442/" name="DC.relation" />
  405. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/BibTeX/epprod-eprint-2442.bib" title="BibTeX" type="text/plain" />
  406. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/ContextObject/epprod-eprint-2442.xml" title="OpenURL ContextObject" type="text/xml" />
  407. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/ContextObject::Dissertation/epprod-eprint-2442.xml" title="OpenURL Dissertation" type="text/xml" />
  408. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/ContextObject::Journal/epprod-eprint-2442.xml" title="OpenURL Journal" type="text/xml" />
  409. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/DC/epprod-eprint-2442.txt" title="Dublin Core" type="text/plain" />
  410. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/DIDL/epprod-eprint-2442.xml" title="DIDL" type="text/xml" />
  411. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/EndNote/epprod-eprint-2442.enw" title="EndNote" type="text/plain" />
  412. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/HTML/epprod-eprint-2442.html" title="HTML Citation" type="text/html; charset=utf-8" />
  413. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/METS/epprod-eprint-2442.xml" title="METS" type="text/xml" />
  414. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/MODS/epprod-eprint-2442.xml" title="MODS" type="text/xml" />
  415. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/RIS/epprod-eprint-2442.ris" title="Reference Manager" type="text/plain" />
  416. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/Refer/epprod-eprint-2442.refer" title="Refer" type="text/plain" />
  417. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/Simple/epprod-eprint-2442text" title="Simple Metadata" type="text/plain" />
  418. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/Text/epprod-eprint-2442.txt" title="ASCII Citation" type="text/plain; charset=utf-8" />
  419. <link rel="alternate" href="http://eprints.utas.edu.au/cgi/export/2442/XML/epprod-eprint-2442.xml" title="EP3 XML" type="text/xml" />
  420.  
  421. </head>
  422. <body bgcolor="#ffffff" text="#000000" onLoad="loadRoutine(); MM_preloadImages('images/eprints/ePrints_banner_r5_c5_f2.gif','images/eprints/ePrints_banner_r5_c7_f2.gif','images/eprints/ePrints_banner_r5_c8_f2.gif','images/eprints/ePrints_banner_r5_c9_f2.gif','images/eprints/ePrints_banner_r5_c10_f2.gif','images/eprints/ePrints_banner_r5_c11_f2.gif','images/eprints/ePrints_banner_r6_c4_f2.gif')">
  423. <div class="ep_noprint"><noscript><style type="text/css">@import url(http://eprints.utas.edu.au/style/nojs.css);</style></noscript></div>
  424.  
  425.  
  426.  
  427.  
  428. <table width="795" border="0" cellspacing="0" cellpadding="0">
  429. <tr>
  430. <td><script language="JavaScript1.2">mmLoadMenus();</script>
  431. <table border="0" cellpadding="0" cellspacing="0" width="795">
  432. <!-- fwtable fwsrc="eprints_banner_final2.png" fwbase="ePrints_banner.gif" fwstyle="Dreamweaver" fwdocid = "1249563342" fwnested="0" -->
  433. <tr>
  434. <td><img src="/images/eprints/spacer.gif" width="32" height="1" border="0" alt="" /></td>
  435. <td><img src="/images/eprints/spacer.gif" width="104" height="1" border="0" alt="" /></td>
  436. <td><img src="/images/eprints/spacer.gif" width="44" height="1" border="0" alt="" /></td>
  437. <td><img src="/images/eprints/spacer.gif" width="105" height="1" border="0" alt="" /></td>
  438. <td><img src="/images/eprints/spacer.gif" width="41" height="1" border="0" alt="" /></td>
  439. <td><img src="/images/eprints/spacer.gif" width="16" height="1" border="0" alt="" /></td>
  440. <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  441. <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  442. <td><img src="/images/eprints/spacer.gif" width="68" height="1" border="0" alt="" /></td>
  443. <td><img src="/images/eprints/spacer.gif" width="82" height="1" border="0" alt="" /></td>
  444. <td><img src="/images/eprints/spacer.gif" width="69" height="1" border="0" alt="" /></td>
  445. <td><img src="/images/eprints/spacer.gif" width="98" height="1" border="0" alt="" /></td>
  446. <td><img src="/images/eprints/spacer.gif" width="1" height="1" border="0" alt="" /></td>
  447. </tr>
  448. <tr>
  449. <td colspan="12"><img name="ePrints_banner_r1_c1" src="/images/eprints/ePrints_banner_r1_c1.gif" width="795" height="10" border="0" alt="" /></td>
  450. <td><img src="/images/eprints/spacer.gif" width="1" height="10" border="0" alt="" /></td>
  451. </tr>
  452. <tr>
  453. <td rowspan="6"><img name="ePrints_banner_r2_c1" src="/images/eprints/ePrints_banner_r2_c1.gif" width="32" height="118" border="0" alt="" /></td>
  454. <td rowspan="5"><a href="http://www.utas.edu.au/"><img name="ePrints_banner_r2_c2" src="/images/eprints/ePrints_banner_r2_c2.gif" width="104" height="103" border="0" alt="" /></a></td>
  455. <td colspan="10"><img name="ePrints_banner_r2_c3" src="/images/eprints/ePrints_banner_r2_c3.gif" width="659" height="41" border="0" alt="" /></td>
  456. <td><img src="/images/eprints/spacer.gif" width="1" height="41" border="0" alt="" /></td>
  457. </tr>
  458. <tr>
  459. <td colspan="3"><a href="http://eprints.utas.edu.au/"><img name="ePrints_banner_r3_c3" src="/images/eprints/ePrints_banner_r3_c3.gif" width="190" height="31" border="0" alt="" /></a></td>
  460. <td rowspan="2" colspan="7"><img name="ePrints_banner_r3_c6" src="/images/eprints/ePrints_banner_r3_c6.gif" width="469" height="37" border="0" alt="" /></td>
  461. <td><img src="/images/eprints/spacer.gif" width="1" height="31" border="0" alt="" /></td>
  462. </tr>
  463. <tr>
  464. <td colspan="3"><img name="ePrints_banner_r4_c3" src="/images/eprints/ePrints_banner_r4_c3.gif" width="190" height="6" border="0" alt="" /></td>
  465. <td><img src="/images/eprints/spacer.gif" width="1" height="6" border="0" alt="" /></td>
  466. </tr>
  467. <tr>
  468. <td colspan="2"><img name="ePrints_banner_r5_c3" src="/images/eprints/ePrints_banner_r5_c3.gif" width="149" height="1" border="0" alt="" /></td>
  469. <td rowspan="2" colspan="2"><a href="/information.html" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821132634_0,0,25,null,'ePrints_banner_r5_c5');MM_swapImage('ePrints_banner_r5_c5','','/images/eprints/ePrints_banner_r5_c5_f2.gif',1);"><img name="ePrints_banner_r5_c5" src="/images/eprints/ePrints_banner_r5_c5.gif" width="57" height="25" border="0" alt="About" /></a></td>
  470. <td rowspan="2"><a href="/view/" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133021_1,0,25,null,'ePrints_banner_r5_c7');MM_swapImage('ePrints_banner_r5_c7','','/images/eprints/ePrints_banner_r5_c7_f2.gif',1);"><img name="ePrints_banner_r5_c7" src="/images/eprints/ePrints_banner_r5_c7.gif" width="68" height="25" border="0" alt="Browse" /></a></td>
  471. <td rowspan="2"><a href="/perl/search/simple" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133201_2,0,25,null,'ePrints_banner_r5_c8');MM_swapImage('ePrints_banner_r5_c8','','/images/eprints/ePrints_banner_r5_c8_f2.gif',1);"><img name="ePrints_banner_r5_c8" src="/images/eprints/ePrints_banner_r5_c8.gif" width="68" height="25" border="0" alt="Search" /></a></td>
  472. <td rowspan="2"><a href="/perl/register" onMouseOut="MM_swapImgRestore();MM_startTimeout();" onMouseOver="MM_showMenu(window.mm_menu_1018171924_3,0,25,null,'ePrints_banner_r5_c9');MM_swapImage('ePrints_banner_r5_c9','','/images/eprints/ePrints_banner_r5_c9_f2.gif',1);"><img name="ePrints_banner_r5_c9" src="/images/eprints/ePrints_banner_r5_c9.gif" width="68" height="25" border="0" alt="register" /></a></td>
  473. <td rowspan="2"><a href="/perl/users/home" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133422_4,0,25,null,'ePrints_banner_r5_c10');MM_swapImage('ePrints_banner_r5_c10','','/images/eprints/ePrints_banner_r5_c10_f2.gif',1);"><img name="ePrints_banner_r5_c10" src="/images/eprints/ePrints_banner_r5_c10.gif" width="82" height="25" border="0" alt="user area" /></a></td>
  474. <td rowspan="2"><a href="/help/" onMouseOut="MM_swapImgRestore();MM_startTimeout()" onMouseOver="MM_showMenu(window.mm_menu_0821133514_5,0,25,null,'ePrints_banner_r5_c11');MM_swapImage('ePrints_banner_r5_c11','','/images/eprints/ePrints_banner_r5_c11_f2.gif',1);"><img name="ePrints_banner_r5_c11" src="/images/eprints/ePrints_banner_r5_c11.gif" width="69" height="25" border="0" alt="Help" /></a></td>
  475. <td rowspan="3" colspan="4"><img name="ePrints_banner_r5_c12" src="/images/eprints/ePrints_banner_r5_c12.gif" width="98" height="40" border="0" alt="" /></td>
  476. <td><img src="/images/eprints/spacer.gif" width="1" height="1" border="0" alt="" /></td>
  477. </tr>
  478. <tr>
  479. <td rowspan="2"><img name="ePrints_banner_r6_c3" src="/images/eprints/ePrints_banner_r6_c3.gif" width="44" height="39" border="0" alt="ePrints home" /></td>
  480. <td><a href="/" onMouseOut="MM_swapImgRestore()" onMouseOver="MM_swapImage('ePrints_banner_r6_c4','','/images/eprints/ePrints_banner_r6_c4_f2.gif',1);"><img name="ePrints_banner_r6_c4" src="/images/eprints/ePrints_banner_r6_c4.gif" width="105" height="24" border="0" alt="ePrints home" /></a></td>
  481. <td><img src="/images/eprints/spacer.gif" width="1" height="24" border="0" alt="" /></td>
  482. </tr>
  483. <tr>
  484. <td><img name="ePrints_banner_r7_c2" src="/images/eprints/ePrints_banner_r7_c2.gif" width="104" height="15" border="0" alt="" /></td>
  485. <td colspan="8"><img name="ePrints_banner_r7_c4" src="/images/eprints/ePrints_banner_r7_c4.gif" width="517" height="15" border="0" alt="" /></td>
  486. <td><img src="/images/eprints/spacer.gif" width="1" height="15" border="0" alt="" /></td>
  487. </tr>
  488. </table></td>
  489. </tr>
  490. <tr><td><table width="100%" style="font-size: 90%; border: solid 1px #ccc; padding: 3px"><tr>
  491. <td align="left"><a href="http://eprints.utas.edu.au/cgi/users/home">Login</a> | <a href="http://eprints.utas.edu.au/cgi/register">Create Account</a></td>
  492. <td align="right" style="white-space: nowrap">
  493. <form method="get" accept-charset="utf-8" action="http://eprints.utas.edu.au/cgi/search" style="display:inline">
  494. <input class="ep_tm_searchbarbox" size="20" type="text" name="q" />
  495. <input class="ep_tm_searchbarbutton" value="Search" type="submit" name="_action_search" />
  496. <input type="hidden" name="_order" value="bytitle" />
  497. <input type="hidden" name="basic_srchtype" value="ALL" />
  498. <input type="hidden" name="_satisfyall" value="ALL" />
  499. </form>
  500. </td>
  501. </tr></table></td></tr>
  502. <tr>
  503. <td class="toplinks"><!-- InstanceBeginEditable name="content" -->
  504.  
  505.  
  506. <div align="center">
  507. <table width="720" class="ep_tm_main"><tr><td align="left">
  508. <h1 class="ep_tm_pagetitle">A role for the tissue factor pathway in the pathogenesis of the antiphospholipid syndrome</h1>
  509. <p style="margin-bottom: 1em" class="not_ep_block"><span class="person_name">Lean, Sim Yee</span> and <span class="person_name">Adams, M.J.</span> (2007) <xhtml:em>A role for the tissue factor pathway in the pathogenesis of the antiphospholipid syndrome.</xhtml:em> Australian Journal of Medical Science, 28 (3). pp. 99-107. ISSN 1038-1643</p><p style="margin-bottom: 1em" class="not_ep_block"></p><table style="margin-bottom: 1em" class="not_ep_block"><tr><td valign="top" style="text-align:center"><a href="http://eprints.utas.edu.au/2442/1/Adams_and_Lean_2007.pdf"><img alt="[img]" src="http://eprints.utas.edu.au/style/images/fileicons/application_pdf.png" class="ep_doc_icon" border="0" /></a></td><td valign="top"><a href="http://eprints.utas.edu.au/2442/1/Adams_and_Lean_2007.pdf"><span class="ep_document_citation">PDF</span></a> - Full text restricted - Requires a PDF viewer<br />317Kb</td><td><form method="get" accept-charset="utf-8" action="http://eprints.utas.edu.au/cgi/request_doc"><input accept-charset="utf-8" value="3195" name="docid" type="hidden" /><div class=""><input value="Request a copy" name="_action_null" class="ep_form_action_button" onclick="return EPJS_button_pushed( '_action_null' )" type="submit" /> </div></form></td></tr></table><p style="margin-bottom: 1em" class="not_ep_block">Official URL: <a href="http://www.aims.org.au/c/">http://www.aims.org.au/c/</a></p><div class="not_ep_block"><h2>Abstract</h2><p style="padding-bottom: 16px; text-align: left; margin: 1em auto 0em auto">The antiphospholipid syndrome (aPS) is a systemic autoimmune disorder that is characterised by&#13;
  510. laboratory markers of antiphospholipid antibodies (aPL) as well as clinical manifestations such as arterial&#13;
  511. and venous thrombosis, recurrent pregnancy loss and thrombocytopaenia. Although it is unclear precisely&#13;
  512. what mechanism(s) lead to thrombosis in aPS, it is probable that the contribution of aPL such as anti-β-2-&#13;
  513. glycoprotein-1 (anti-β2GP1) is signifi cant. Indeed, there is increasing evidence that aPL may interfere with&#13;
  514. the tissue factor (TF) pathway of blood coagulation and its natural regulator tissue factor pathway inhibitor&#13;
  515. (TFPI), thus contributing toward the development of thrombosis in aPS. This paper will therefore review&#13;
  516. 1) the TF pathway of blood coagulation and TFPI, 2) clinical and laboratory aspects of aPL and aPS,&#13;
  517. and 3) interactions of aPL with the TF pathway, to highlight the potential signifi cance of these in the&#13;
  518. pathogenesis of aPS.</p></div><table style="margin-bottom: 1em" cellpadding="3" class="not_ep_block" border="0"><tr><th valign="top" class="ep_row">Item Type:</th><td valign="top" class="ep_row">Article</td></tr><tr><th valign="top" class="ep_row">Keywords:</th><td valign="top" class="ep_row">Antiphospholipid antibodies; Antiphospholipid syndrome; Thrombosis; Tissue factor; Tissue factor pathway inhibitor</td></tr><tr><th valign="top" class="ep_row">Subjects:</th><td valign="top" class="ep_row"><a href="http://eprints.utas.edu.au/view/subjects/321008.html">320000 Medical and Health Sciences &gt; 321000 Clinical Sciences &gt; 321008 Haematology</a></td></tr><tr><th valign="top" class="ep_row">ID Code:</th><td valign="top" class="ep_row">2442</td></tr><tr><th valign="top" class="ep_row">Deposited By:</th><td valign="top" class="ep_row"><span class="ep_name_citation"><span class="person_name">Dr Murray J Adams</span></span></td></tr><tr><th valign="top" class="ep_row">Deposited On:</th><td valign="top" class="ep_row">15 Nov 2007 12:28</td></tr><tr><th valign="top" class="ep_row">Last Modified:</th><td valign="top" class="ep_row">09 Jan 2008 02:30</td></tr><tr><th valign="top" class="ep_row">ePrint Statistics:</th><td valign="top" class="ep_row"><a target="ePrintStats" href="/es/index.php?action=show_detail_eprint;id=2442;">View statistics for this ePrint</a></td></tr></table><p align="right">Repository Staff Only: <a href="http://eprints.utas.edu.au/cgi/users/home?screen=EPrint::View&amp;eprintid=2442">item control page</a></p>
  519. </td></tr></table>
  520. </div>
  521.  
  522.  
  523.  
  524. <!-- InstanceEndEditable --></td>
  525. </tr>
  526. <tr>
  527. <td><!-- #BeginLibraryItem "/Library/footer_eprints.lbi" -->
  528. <table width="795" border="0" align="left" cellpadding="0" class="footer">
  529. <tr valign="top">
  530. <td colspan="2"><div align="center"><a href="http://www.utas.edu.au">UTAS home</a> | <a href="http://www.utas.edu.au/library/">Library home</a> | <a href="/">ePrints home</a> | <a href="/contact.html">contact</a> | <a href="/information.html">about</a> | <a href="/view/">browse</a> | <a href="/perl/search/simple">search</a> | <a href="/perl/register">register</a> | <a href="/perl/users/home">user area</a> | <a href="/help/">help</a></div><br /></td>
  531. </tr>
  532. <tr><td colspan="2"><p><img src="/images/eprints/footerline.gif" width="100%" height="4" /></p></td></tr>
  533. <tr valign="top">
  534. <td width="68%" class="footer">Authorised by the University Librarian<br />
  535. © University of Tasmania ABN 30 764 374 782<br />
  536. <a href="http://www.utas.edu.au/cricos/">CRICOS Provider Code 00586B</a> | <a href="http://www.utas.edu.au/copyright/copyright_disclaimers.html">Copyright &amp; Disclaimers</a> | <a href="http://www.utas.edu.au/accessibility/index.html">Accessibility</a> | <a href="http://eprints.utas.edu.au/feedback/">Site Feedback</a>  </td>
  537. <td width="32%"><div align="right">
  538. <p align="right" class="NoPrint"><a href="http://www.utas.edu.au/"><img src="http://www.utas.edu.au/shared/logos/unioftasstrip.gif" alt="University of Tasmania Home Page" width="260" height="16" border="0" align="right" /></a></p>
  539. <p align="right" class="NoPrint"><a href="http://www.utas.edu.au/"><br />
  540. </a></p>
  541. </div></td>
  542. </tr>
  543. <tr valign="top">
  544. <td><p>  </p></td>
  545. <td><div align="right"><span class="NoPrint"><a href="http://www.eprints.org/software/"><img src="/images/eprintslogo.gif" alt="ePrints logo" width="77" height="29" border="0" align="bottom" /></a></span></div></td>
  546. </tr>
  547. </table>
  548. <!-- #EndLibraryItem -->
  549. <div align="center"></div></td>
  550. </tr>
  551. </table>
  552.  
  553. </body>
  554. </html>